nor-NOHA monoacetate
Based on 7 publication(s) in Google Scholar
nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.99%
- CAS No.: 2250019-93-1
- 화학식: C7H16N4O5
- 분자량:236.23
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-19548A
BEC hydrochlorideArginaseII Inhibitor -
HY-15775
Arginase inhibitor 1Arginases I/II Inhibitor -
HY-101979
NumidargistatArginase Inhibitor -
HY-18732A
L-NMMA acetateEndogenous Metabolite -
HY-10256
Adezmapimodp38 MAPK Inhibitor -
HY-Y0399
L-NorvalineArginase Inhibitor -
HY-13818
StatticSTAT3 Inhibitor -
HY-16749
PexidartinibCSF1R/c-Kit Inhibitor -
HY-P70543
TGF beta 1/TGFB1 Protein, Human (HEK293) -
HY-W062216
2-AminoimidazoleAntibiofilm Agent -
HY-D1056
Lipopolysaccharides, from E. coli O55:B5Endotoxin -
HY-W010510
DL-Norvaline
Publications Citing Use of MedChemExpress (MCE) nor-NOHA monoacetate
More- Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
- Free Radic Biol Med. 2026 Apr:247:516-527. [Abstract]
- Chin Med. 2026 May 28;21(1):151. [Abstract]
- Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]
- FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
- Clin Immunol. 2024 Nov:268:110355. [Abstract]
- Res Sq. 2026 May 8:rs.3.rs-9404453. [Abstract]
Customer Validation & Images
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Bio/Physico-chemical Assay
Biological Activity
제품 설명
In Vitro
nor-NOHA monoacetate (0.1-1 mM, 72 h) induces apoptosis in a dose-dependent manner under hypoxia (1.5% O2) in K562 cells[1].
nor-NOHA monoacetate (1 mM, 72 h) attenuates hypoxia-mediated resistance towards imatinib in K562 or KCL22 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
nor-NOHA monoacetate (100 mg/kg, i.v., once time) increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2250019-93-1
-
Appearance Solid
-
분자량 236.23
-
화학식 C7H16N4O5
-
Color White to off-white
-
SMILES
N[C@H](C(O)=O)CCNC(NO)=N.O=C(C)O
-
Synonyms
Nω-Hydroxy-nor-L-arginine monoacetate
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Dec 11;188(25):7291-7308.e23. PMID: 41161316
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7291-7308.e23. [Abstract]
Bar plots showing proportions of TNF-α+ T cells in fetal liver whole blood following PMA simulation. T cells were cultured alone (light green) or co-cultured with matched fetal neutrophils (orange) in the presence or absence of ARG1 inhibitor (nonor-NOHA monoacetate; overnight) or L-arginine supplementation, as indicated on the x axis.
-
Free Radic Biol Med
Endothelial Arg2 regulates HIMM-induced mitochondrial hyperfission via affecting arginine metabolism. [Abstract]2026 Apr:247:516-527. PMID: 41720362 -
Chin Med
Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells. [Abstract]2026 May 28;21(1):151. PMID: 42210399 -
Front Cell Dev Biol
mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. [Abstract]2021 Dec 23;9:741911. PMID: 35004668
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2021 Dec 23;9:741911. [Abstract]
nor-NOHA monoacetate (nor-NOHA) efficiently reduced immunosuppressive activity. Arg1 inhibitor (nor-NOHA) and/or iNOS inhibitor [L-NG-Monomethylarginine, Acetate Salt (L-NMMA)] were added in PMN-MDSCs’ suppressive function assays.
-
FASEB J
Spatial Metabolism of Primary Limited Cutaneous Amyloidosis Based on Mass Spectrometry Imaging. [Abstract]2025 Sep 30;39(18):e71057. PMID: 40955599
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
nonor-NOHA monoacetate (1, 10, 50, 100 μM) increased HaCaT cell viability.
nor-NOHA monoacetate purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Sep 30;39(18):e71057. [Abstract]
nonor-NOHA monoacetate (100 μM) increased K5 expression in HaCaT cells.
-
Clin Immunol
MAPK signaling pathway induced LOX-1+ polymorphonuclear myeloid-derived suppressor cells in biliary atresia. [Abstract]2024 Nov:268:110355. PMID: 39237078 -
Res Sq
Protective coinfection: influenza reprograms myeloid cells to limit CD8 T cell-mediated malaria pathology. [Abstract]2026 May 8:rs.3.rs-9404453. PMID: 42147182
용액&용해도
In Vitro:
DMSO : 100 mg/mL (423.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (211.66 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (423.32 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
순도&문서
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [Content Brief]
[2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.2332 mL | 21.1658 mL | 42.3316 mL | 105.8291 mL |
| 5 mM | 0.8466 mL | 4.2332 mL | 8.4663 mL | 21.1658 mL | |
| 10 mM | 0.4233 mL | 2.1166 mL | 4.2332 mL | 10.5829 mL | |
| 15 mM | 0.2822 mL | 1.4111 mL | 2.8221 mL | 7.0553 mL | |
| 20 mM | 0.2117 mL | 1.0583 mL | 2.1166 mL | 5.2915 mL | |
| 25 mM | 0.1693 mL | 0.8466 mL | 1.6933 mL | 4.2332 mL | |
| 30 mM | 0.1411 mL | 0.7055 mL | 1.4111 mL | 3.5276 mL | |
| 40 mM | 0.1058 mL | 0.5291 mL | 1.0583 mL | 2.6457 mL | |
| 50 mM | 0.0847 mL | 0.4233 mL | 0.8466 mL | 2.1166 mL | |
| 60 mM | 0.0706 mL | 0.3528 mL | 0.7055 mL | 1.7638 mL | |
| 80 mM | 0.0529 mL | 0.2646 mL | 0.5291 mL | 1.3229 mL | |
| 100 mM | 0.0423 mL | 0.2117 mL | 0.4233 mL | 1.0583 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
nor-NOHA monoacetate Related Classifications
HY-112885B Related Classifications
Powered by Bioz